Which has higher valuation and earnings, BVS or ITGR?

Integer has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $581.85M 2.05 $22.73M $0.77 18.52 Integer $1.84B 2.31 $102.81M $3.66 34.24

Is BVS or ITGR more profitable?

Bioventus has a net margin of 9.36% compared to Integer's net margin of 6.97%. Bioventus' return on equity of 28.08% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 9.36% 28.08% 9.82% Integer 6.97% 12.79% 6.48%

Does the media favor BVS or IRTC?

In the previous week, iRhythm Technologies had 14 more articles in the media than Bioventus. MarketBeat recorded 21 mentions for iRhythm Technologies and 7 mentions for Bioventus. Bioventus' average media sentiment score of 1.14 beat iRhythm Technologies' score of 0.50 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 5 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, BVS or LIVN?

Bioventus has higher earnings, but lower revenue than LivaNova. Bioventus is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $581.85M 2.05 $22.73M $0.77 18.52 LivaNova $1.39B 3.26 -$242.47M $3.38 24.33

Is BVS or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to Bioventus' net margin of 9.36%. Bioventus' return on equity of 28.08% beat LivaNova's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 9.36% 28.08% 9.82% LivaNova 12.82% 16.35% 7.76%

Does the media favor BVS or LIVN?

In the previous week, Bioventus had 4 more articles in the media than LivaNova. MarketBeat recorded 7 mentions for Bioventus and 3 mentions for LivaNova. Bioventus' average media sentiment score of 1.14 beat LivaNova's score of 0.89 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, BVS or HAE?

Haemonetics has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $581.85M 2.05 $22.73M $0.77 18.52 Haemonetics $1.33B 3.10 $97.31M $2.04 44.54

Is BVS or HAE more profitable?

Bioventus has a net margin of 9.36% compared to Haemonetics' net margin of 7.12%. Bioventus' return on equity of 28.08% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 9.36% 28.08% 9.82% Haemonetics 7.12% 27.55% 9.65%

Does the media favor BVS or HAE?

In the previous week, Haemonetics had 9 more articles in the media than Bioventus. MarketBeat recorded 16 mentions for Haemonetics and 7 mentions for Bioventus. Bioventus' average media sentiment score of 1.14 beat Haemonetics' score of 0.54 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 6 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, BVS or TMDX?

TransMedics Group has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $581.85M 2.05 $22.73M $0.77 18.52 TransMedics Group $605.49M 5.06 $190.29M $3.89 22.77

Does the media favor BVS or TMDX?

In the previous week, Bioventus and Bioventus both had 7 articles in the media. Bioventus' average media sentiment score of 1.14 beat TransMedics Group's score of 0.34 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Bioventus (BVS) Competitors

$14.26 +0.37 (+2.66%)

Closing price 04:00 PM Eastern

Extended Trading

$14.19 -0.07 (-0.48%)

As of 05:10 PM Eastern

Compare

BVS vs. ITGR, IRTC, LIVN, HAE, and TMDX

Should you buy Bioventus stock or one of its competitors? Bioventus's main competitors and comparable companies include Integer (ITGR), iRhythm Technologies (IRTC), LivaNova (LIVN), Haemonetics (HAE), and TransMedics Group (TMDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Bioventus compare to Integer?

Bioventus (NASDAQ:BVS) and Integer (NYSE:ITGR) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Bioventus presently has a consensus target price of $16.25, suggesting a potential upside of 13.96%. Integer has a consensus target price of $109.86, suggesting a potential downside of 12.35%. Given Bioventus' stronger consensus rating and higher possible upside, analysts clearly believe Bioventus is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 33.5% of Bioventus shares are owned by company insiders. Comparatively, 1.1% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Integer has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$581.85M	2.05	$22.73M	$0.77	18.52
Integer	$1.84B	2.31	$102.81M	$3.66	34.24

Bioventus has a net margin of 9.36% compared to Integer's net margin of 6.97%. Bioventus' return on equity of 28.08% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
Integer	6.97%	12.79%	6.48%

In the previous week, Bioventus had 7 more articles in the media than Integer. MarketBeat recorded 7 mentions for Bioventus and 0 mentions for Integer. Bioventus' average media sentiment score of 1.14 beat Integer's score of 0.75 indicating that Bioventus is being referred to more favorably in the media.

Company	Overall Sentiment
Bioventus	Positive
Integer	Positive

Bioventus has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Integer has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Summary

Bioventus beats Integer on 11 of the 17 factors compared between the two stocks.

How does Bioventus compare to iRhythm Technologies?

Bioventus (NASDAQ:BVS) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

62.9% of Bioventus shares are owned by institutional investors. 33.5% of Bioventus shares are owned by company insiders. Comparatively, 1.0% of iRhythm Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bioventus has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$581.85M	2.05	$22.73M	$0.77	18.52
iRhythm Technologies	$747.14M	5.58	-$44.55M	-$0.43	N/A

Bioventus presently has a consensus target price of $16.25, suggesting a potential upside of 13.96%. iRhythm Technologies has a consensus target price of $179.93, suggesting a potential upside of 42.30%. Given iRhythm Technologies' higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

Bioventus has a net margin of 9.36% compared to iRhythm Technologies' net margin of -1.69%. Bioventus' return on equity of 28.08% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
iRhythm Technologies	-1.69%	10.11%	1.53%

In the previous week, iRhythm Technologies had 14 more articles in the media than Bioventus. MarketBeat recorded 21 mentions for iRhythm Technologies and 7 mentions for Bioventus. Bioventus' average media sentiment score of 1.14 beat iRhythm Technologies' score of 0.50 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	5 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

Summary

Bioventus beats iRhythm Technologies on 10 of the 17 factors compared between the two stocks.

How does Bioventus compare to LivaNova?

Bioventus (NASDAQ:BVS) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

LivaNova has a net margin of 12.82% compared to Bioventus' net margin of 9.36%. Bioventus' return on equity of 28.08% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
LivaNova	12.82%	16.35%	7.76%

In the previous week, Bioventus had 4 more articles in the media than LivaNova. MarketBeat recorded 7 mentions for Bioventus and 3 mentions for LivaNova. Bioventus' average media sentiment score of 1.14 beat LivaNova's score of 0.89 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has higher earnings, but lower revenue than LivaNova. Bioventus is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$581.85M	2.05	$22.73M	$0.77	18.52
LivaNova	$1.39B	3.26	-$242.47M	$3.38	24.33

62.9% of Bioventus shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 33.5% of Bioventus shares are held by company insiders. Comparatively, 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bioventus has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Bioventus presently has a consensus target price of $16.25, indicating a potential upside of 13.96%. LivaNova has a consensus target price of $83.50, indicating a potential upside of 1.56%. Given Bioventus' stronger consensus rating and higher possible upside, analysts clearly believe Bioventus is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Summary

Bioventus and LivaNova tied by winning 8 of the 16 factors compared between the two stocks.

How does Bioventus compare to Haemonetics?

Bioventus (NASDAQ:BVS) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Bioventus has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Haemonetics has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Bioventus has a net margin of 9.36% compared to Haemonetics' net margin of 7.12%. Bioventus' return on equity of 28.08% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
Haemonetics	7.12%	27.55%	9.65%

In the previous week, Haemonetics had 9 more articles in the media than Bioventus. MarketBeat recorded 16 mentions for Haemonetics and 7 mentions for Bioventus. Bioventus' average media sentiment score of 1.14 beat Haemonetics' score of 0.54 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	6 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Haemonetics has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$581.85M	2.05	$22.73M	$0.77	18.52
Haemonetics	$1.33B	3.10	$97.31M	$2.04	44.54

Bioventus currently has a consensus price target of $16.25, indicating a potential upside of 13.96%. Haemonetics has a consensus price target of $90.89, indicating a potential upside of 0.03%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

62.9% of Bioventus shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 33.5% of Bioventus shares are held by insiders. Comparatively, 2.1% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Bioventus and Haemonetics tied by winning 8 of the 16 factors compared between the two stocks.

How does Bioventus compare to TransMedics Group?

Bioventus (NASDAQ:BVS) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Bioventus has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market.

62.9% of Bioventus shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 33.5% of Bioventus shares are held by insiders. Comparatively, 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bioventus presently has a consensus target price of $16.25, indicating a potential upside of 13.96%. TransMedics Group has a consensus target price of $124.18, indicating a potential upside of 40.19%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

TransMedics Group has a net margin of 22.69% compared to Bioventus' net margin of 9.36%. Bioventus' return on equity of 28.08% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
TransMedics Group	22.69%	15.88%	5.95%

In the previous week, Bioventus and Bioventus both had 7 articles in the media. Bioventus' average media sentiment score of 1.14 beat TransMedics Group's score of 0.34 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransMedics Group has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$581.85M	2.05	$22.73M	$0.77	18.52
TransMedics Group	$605.49M	5.06	$190.29M	$3.89	22.77

Summary

TransMedics Group beats Bioventus on 10 of the 16 factors compared between the two stocks.

Get Bioventus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BVS vs. The Competition

Export

Metric	Bioventus	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.19B	$5.80B	$6.97B	$13.05B
Dividend Yield	N/A	1.76%	2.58%	10.72%
P/E Ratio	18.52	26.26	269.86	25.30
Price / Sales	2.05	40.12	598.68	101.54
Price / Cash	10.91	33.59	70.53	50.75
Price / Book	4.30	5.91	13.08	6.33
Net Income	$22.73M	$148.67M	$3.45B	$347.70M
7 Day Performance	0.92%	1.86%	1.14%	1.08%
1 Month Performance	23.36%	4.58%	1.81%	1.04%
1 Year Performance	94.28%	8.69%	67.69%	20.77%

Bioventus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BVS Bioventus	4.5955 of 5 stars	$14.26 +2.7%	$16.25 +14.0%	+84.5%	$1.19B	$581.85M	18.52	1,200	Positive News
ITGR Integer	2.3128 of 5 stars	$125.06 -0.8%	$109.86 -12.2%	+14.0%	$4.26B	$1.84B	34.17	11,000	Analyst Downgrade
IRTC iRhythm Technologies	4.0246 of 5 stars	$127.84 -0.2%	$179.36 +40.3%	-26.2%	$4.21B	$747.14M	N/A	2,400	Positive News High Trading Volume
LIVN LivaNova	2.3492 of 5 stars	$76.22 +0.6%	$83.50 +9.6%	+54.9%	$4.17B	$1.39B	22.55	3,300
HAE Haemonetics	1.8572 of 5 stars	$87.51 +2.9%	$90.89 +3.9%	+67.7%	$3.86B	$1.33B	42.89	3,009	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BVS) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventus (BVS) Competitors

BVS vs. ITGR, IRTC, LIVN, HAE, and TMDX

How does Bioventus compare to Integer?

Summary

How does Bioventus compare to iRhythm Technologies?

Summary

How does Bioventus compare to LivaNova?

Summary

How does Bioventus compare to Haemonetics?

Summary

How does Bioventus compare to TransMedics Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS vs. The Competition

Bioventus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventus (BVS) Competitors

BVS vs. ITGR, IRTC, LIVN, HAE, and TMDX

How does Bioventus compare to Integer?

Do analysts prefer BVS or ITGR?

Do institutionals and insiders hold more shares of BVS or ITGR?

Which has higher valuation and earnings, BVS or ITGR?

Is BVS or ITGR more profitable?

Does the media prefer BVS or ITGR?

Which has more volatility & risk, BVS or ITGR?

Summary

How does Bioventus compare to iRhythm Technologies?

Do insiders & institutionals hold more shares of BVS or IRTC?

Which has stronger valuation & earnings, BVS or IRTC?

Do analysts rate BVS or IRTC?

Is BVS or IRTC more profitable?

Does the media favor BVS or IRTC?

Which has more risk & volatility, BVS or IRTC?

Summary

How does Bioventus compare to LivaNova?

Is BVS or LIVN more profitable?

Does the media favor BVS or LIVN?

Which has preferable valuation & earnings, BVS or LIVN?

Do insiders and institutionals believe in BVS or LIVN?

Which has more volatility and risk, BVS or LIVN?

Do analysts prefer BVS or LIVN?

Summary

How does Bioventus compare to Haemonetics?

Which has more volatility & risk, BVS or HAE?

Is BVS or HAE more profitable?

Does the media favor BVS or HAE?

Which has better earnings and valuation, BVS or HAE?

Do analysts prefer BVS or HAE?

Do institutionals & insiders believe in BVS or HAE?

Summary

How does Bioventus compare to TransMedics Group?

Which has more risk and volatility, BVS or TMDX?

Do institutionals and insiders believe in BVS or TMDX?

Do analysts prefer BVS or TMDX?

Is BVS or TMDX more profitable?

Does the media favor BVS or TMDX?

Which has higher valuation and earnings, BVS or TMDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS vs. The Competition

Bioventus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools